Austria
Every company in the roster headquartered in Austria.
Every company in the roster headquartered in Austria.
4 of 4 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 1 asset: 1 approved | Approved assets only | 18 Nov 2027Ropeginterferon alfa-2b (Besremi) · Phase 3 | — | — | — | — | |
| 1 asset: 1 Ph 2 | CerebrolysinPhase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — | |
Gebro Pharma GmbHPrivate | 1 asset: 1 Ph 3 | PiclidenosonPhase 3 · PsoriasisPartial signal | 31 Aug 2027Piclidenoson · Phase 2 | — | — | — | — |
pharmaandPrivate | 3 assets: 2 approved, 1 other | PanobinostatUS approval withdrawn · Multiple MyelomaPartial signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.